Jyrki Mattila Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Jyrki Mattila.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Jyrki Mattila. Jyrki Mattila is a Director in BIOSPECIFICS TECHNOLOGIES CORP ($BSTCE) and an Executive Vice President in AUXILIUM PHARMACEUTICALS INC ($AUXL) and a Chief Business Officer in Lipocine Inc. ($LPCN) and an Executive VP, Business Dev. in Recro Pharma, Inc. ($REPH).
Address: C/O AUXILIUM PHARMACEUTICALS, INC. 160 WEST GERMANTOWN PIKE NORRISTOWN 19401 PA
Companies in which Jyrki Mattila is an Insider
AUXILIUM PHARMACEUTICALS INC
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of Jyrki Mattila: Executive Vice President
Holdings: 11,520 shares
Latest Transaction: Jun 07 2005
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
BIOSPECIFICS TECHNOLOGIES CORP
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of Jyrki Mattila: Director
Holdings: 15,376 shares
Latest Transaction: May 24 2019
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
Lipocine Inc.
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of Jyrki Mattila: Chief Business Officer
Holdings: 0 shares
Current Value: $0
Latest Transaction: Jan 30 2017
$LPCN Market Capitalization: $68.11M
$LPCN Previous Close: $3.70
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
Recro Pharma, Inc.
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of Jyrki Mattila: Executive VP, Business Dev.
Holdings: 11,500 shares
Current Value: $92,575
Latest Transaction: Jan 04 2018
$REPH Market Capitalization: $98.40M
$REPH Previous Close: $8.05
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
Latest Insider Trading Transactions of Jyrki Mattila
Sentiment: All, AUXL, BSTCE, LPCN, REPH
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 24 2019 | BSTCE | BIOSPECIFICS TECHN ... | Mattila Jyrki | Director | Option Exercise | M | 41.82 | 3,750 | 156,825 | 11,250 | |
| May 24 2019 | BSTCE | BIOSPECIFICS TECHN ... | Mattila Jyrki | Director | Option Exercise | M | 37.64 | 15,000 | 564,600 | 0 | |
| May 24 2019 | BSTCE | BIOSPECIFICS TECHN ... | Mattila Jyrki | Director | Sell | S | 62.06 | 18,750 | 1,163,625 | 376 | 19.1 K to 376 (-98.03 %) |
| May 24 2019 | BSTCE | BIOSPECIFICS TECHN ... | Mattila Jyrki | Director | Buy | M | 41.82 | 3,750 | 156,825 | 19,126 | 15.4 K to 19.1 K (+24.39 %) |
| May 24 2019 | BSTCE | BIOSPECIFICS TECHN ... | Mattila Jyrki | Director | Buy | M | 37.64 | 15,000 | 564,600 | 15,376 | 376 to 15.4 K (+3,989.36 %) |
| Mar 19 2018 | BSTCE | BIOSPECIFICS TECHN ... | Mattila Jyrki | Director | Option Exercise | A | 41.82 | 15,000 | 627,300 | 15,000 | |
| Jan 04 2018 | REPH | Recro Pharma, Inc. | Mattila Jyrki | Executive VP, Busin ... | Option Exercise | A | 9.04 | 23,000 | 207,920 | 23,000 |